Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series

Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of advanced ALK-rearrangement positive non-small-cell lung cancer (NSCLC). Many tolerable adverse events were reported with the use of Alectinib; nevertheless, hemolytic anemia was not mentioned in the...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sayed, Rola, Tehfe, Mustapha, Blais, Normand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858242/
https://www.ncbi.nlm.nih.gov/pubmed/36661690
http://dx.doi.org/10.3390/curroncol30010041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858242/
https://www.ncbi.nlm.nih.gov/pubmed/36661690
http://dx.doi.org/10.3390/curroncol30010041

Ejemplares similares